Literature DB >> 24282707

Impact of Next-Generation Sequencing (NGS) technology on cardiovascular disease research.

Fengping Xu1, Qin Wang, Fangfang Zhang, Yinling Zhu, Qingquan Gu, Liping Wu, Lin Yang, Xu Yang.   

Abstract

In recent years, hundreds of gene loci associated with multiple cardiovascular pathologies and traits have been identified through high-throughput Next-Generation Sequencing (NGS) technology. Due to the increasing efficiency and decreasing cost of NGS, rapid progresses anticipated in the field of CVD research. This review summarizes the main strategies of CV research with NGS at the level of genomics, transcriptomics, epigenetics, and proteomics.

Entities:  

Keywords:  Cardiovascular disease; Next-Generation Sequencing; epigenetics; genomics; proteomics

Year:  2012        PMID: 24282707      PMCID: PMC3839151          DOI: 10.3978/j.issn.2223-3652.2012.06.01

Source DB:  PubMed          Journal:  Cardiovasc Diagn Ther        ISSN: 2223-3652


  12 in total

Review 1.  Genomics of cardiovascular disease.

Authors:  Christopher J O'Donnell; Elizabeth G Nabel
Journal:  N Engl J Med       Date:  2011-12-01       Impact factor: 91.245

Review 2.  Annotating individual human genomes.

Authors:  Ali Torkamani; Ashley A Scott-Van Zeeland; Eric J Topol; Nicholas J Schork
Journal:  Genomics       Date:  2011-08-02       Impact factor: 5.736

Review 3.  Protein biomarker discovery and validation: the long and uncertain path to clinical utility.

Authors:  Nader Rifai; Michael A Gillette; Steven A Carr
Journal:  Nat Biotechnol       Date:  2006-08       Impact factor: 54.908

Review 4.  Next steps in cardiovascular disease genomic research--sequencing, epigenetics, and transcriptomics.

Authors:  Renate B Schnabel; Andrea Baccarelli; Honghuang Lin; Patrick T Ellinor; Emelia J Benjamin
Journal:  Clin Chem       Date:  2011-11-18       Impact factor: 8.327

Review 5.  Genomewide association studies in cardiovascular disease--an update 2011.

Authors:  Tanja Zeller; Stefan Blankenberg; Patrick Diemert
Journal:  Clin Chem       Date:  2011-11-28       Impact factor: 8.327

6.  A pipeline that integrates the discovery and verification of plasma protein biomarkers reveals candidate markers for cardiovascular disease.

Authors:  Terri A Addona; Xu Shi; Hasmik Keshishian; D R Mani; Michael Burgess; Michael A Gillette; Karl R Clauser; Dongxiao Shen; Gregory D Lewis; Laurie A Farrell; Michael A Fifer; Marc S Sabatine; Robert E Gerszten; Steven A Carr
Journal:  Nat Biotechnol       Date:  2011-06-19       Impact factor: 54.908

Review 7.  Proteomics and heart disease: identifying biomarkers of clinical utility.

Authors:  Qin Fu; Jennifer E Van Eyk
Journal:  Expert Rev Proteomics       Date:  2006-04       Impact factor: 3.940

8.  10-years experience with the Athero-Express study.

Authors:  Willem E Hellings; Frans L Moll; Dominique P V de Kleijn; Gerard Pasterkamp
Journal:  Cardiovasc Diagn Ther       Date:  2012-03

Review 9.  The role of proteomics in clinical cardiovascular biomarker discovery.

Authors:  Alistair V G Edwards; Melanie Y White; Stuart J Cordwell
Journal:  Mol Cell Proteomics       Date:  2008-07-30       Impact factor: 5.911

10.  9p21 DNA variants associated with coronary artery disease impair interferon-γ signalling response.

Authors:  Olivier Harismendy; Dimple Notani; Xiaoyuan Song; Nazli G Rahim; Bogdan Tanasa; Nathaniel Heintzman; Bing Ren; Xiang-Dong Fu; Eric J Topol; Michael G Rosenfeld; Kelly A Frazer
Journal:  Nature       Date:  2011-02-10       Impact factor: 49.962

View more
  2 in total

1.  'Longitudinal' topics in Cardiovascular Diagnosis and Therapy (CDT).

Authors:  Paul Schoenhagen; Hussain Isma'eel; Ana Olga Mocumbi
Journal:  Cardiovasc Diagn Ther       Date:  2012-06

Review 2.  Application of Single-Nucleotide Polymorphism-Related Risk Estimates in Identification of Increased Genetic Susceptibility to Cardiovascular Diseases: A Literature Review.

Authors:  Szilvia Fiatal; Róza Ádány
Journal:  Front Public Health       Date:  2018-01-31
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.